Margetuximab

From WikiMD's Wellness Encyclopedia

What Is Margetuximab?[edit | edit source]


What are the uses of this medicine?[edit | edit source]

  • Margetuximab (Margenza) is indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.


How does this medicine work?[edit | edit source]

  • Margetuximab-cmkb binds to the extracellular domain of the human epidermal growth factor receptor 2 protein (HER2).
  • Upon binding to HER2-expressing tumor cells, margetuximab-cmkb inhibits tumor cell proliferation, reduces shedding of the HER2 extracellular domain and mediates antibody-dependent cellular cytotoxicity (ADCC).


Who Should Not Use this medicine ?[edit | edit source]

  • This medicine have no usage limitations


Is this medicine FDA approved?[edit | edit source]

  • It was approved for use in the United States in 2020.


How should this medicine be used?[edit | edit source]

  • Administer Margenza as an intravenous infusion at 15 mg/kg over 120 minutes for the initial dose, then over a minimum of 30 minutes every 3 weeks for all subsequent doses.
  • On days when both Margenza and chemotherapy are to be administered, Margenza may be administered immediately after chemotherapy completion.


What are the dosage forms and brand names of this medicine?[edit | edit source]

This medicine is available in fallowing doasage form: As injections: 250 mg/10 mL (25 mg/mL) in a single-dose vial

This medicine is available in fallowing brand namesː

  • Margenza


What side effects can this medication cause?[edit | edit source]

Common possible side effects and laboratory abnormalities of this medicine include:


What special precautions should I follow?[edit | edit source]

  • Margenza may lead to reductions in left ventricular ejection fraction (LVEF).
  • Evaluate cardiac function prior to and during treatment.
  • Discontinue Margenza treatment for a confirmed clinically significant decrease in left ventricular function.
  • Margenza can cause fetal harm when administered to a pregnant woman.
  • Advise patients of the risk and need for effective contraception.
  • If a significant infusion-associated reaction occurs, slow or interrupt the infusion and administer appropriate medical therapies.


What to do in case of emergency/overdose?[edit | edit source]

  • In case of overdose, call the poison control helpline of your country. In the United States, call 1-800-222-1222.


Can this medicine be used in pregnancy?[edit | edit source]

  • Exposure to Margenza during pregnancy can cause embryo-fetal harm.


Can this medicine be used in children?[edit | edit source]

  • Safety and effectiveness of Margenza have not been established in pediatric patients.


What should I know about storage and disposal of this medication?[edit | edit source]

  • Store vials refrigerated at 2°C to 8°C (36°F to 46°F) in original carton to protect from light until time of use.
  • Do not freeze.
  • Do not shake.


Margetuximab Resources

Contributors: Deepika vegiraju